Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lega, Jean Christophe ^a,b   Bertoletti, Laurent ^b,c,d   Gremillet, Cyrielle ^c   Chapelle, Céline ^d   Mismetti, Patrick ^b,c,d   Cucherat, Michel ^a   Vital Durand, Denis ^a   Laporte, Silvy ^b,e  

^a UNIVERSITÉ LYON 1   (France)

^b University Jean Monnet of Saint Etienne EA3065   (France)

^c HÔPITAL NORD   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; NEW ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

AGE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; KIDNEY FUNCTION; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ATRIAL FIBRILLATION; ORAL DRUG ADMINISTRATION; PROCEDURES; SAFETY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY;

EID: 84898006776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091398     Document Type: Article

References (44)

1. Dulli DA, Stanko H, Levine RL (2003) Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22: 118-123. (Pubitemid 36302428)
2. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, et al. (2008) Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 336: 376-379. (Pubitemid 351300373)
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369-2429.
4. Rupprecht HJ, Blank R (2010) Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 70: 2153-2170.
5. Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115: 15-20.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48: 854-906. (Pubitemid 44175743)
7. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, et al. (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S. (Pubitemid 351892972)
8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, et al. (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349: 1019-1026. (Pubitemid 37087616)
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 365: 981-992.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
12. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, et al. (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123: 2363-2372.
13. Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362: 1691-1698.
14. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, et al. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293: 690-698.
15. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-1912.
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870. (Pubitemid 32537350)
17. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369-2429.
18. Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57: 173-180.
19. Wong SS, Wilczynski NL, Haynes RB (2006) Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 94: 41-47.
20. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR (2005) Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 330: 1179.
21. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: 692-694. (Pubitemid 41647882)
22. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
23. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
25. Team RC (2012) R: A Language and Environment for Statistical Computing. http://www.r-project.org. Accessed 2014 January 12.
26. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
27. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, et al. (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11: 503-511.
28. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, et al. (2012) Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159: 331-339.
29. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, et al. (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33: 2821-2830.
30. Darius H, Clemens A, Healey JS, Avezum A, Rangadham N, et al. (2012) Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY Trial. American Heart Association's Scientific Sessions.
31. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, et al. (2011) Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 155: 660-667, W204.
32. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, et al. (2010) Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 122: 2246-2253.
33. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, et al. (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9: 1157-1163.
34. Food and Drug Administration website. Available: http://wwwfdagov/ downloads/advisorycom-mittees/committeesmeetingmaterials/drugs/ cardiovascularandrenal-drugsadvisorycommittee/ucm226009pdf. Accessed 2013 Jul 2.
35. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, et al. (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32: 2387-2394.
36. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, et al. (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11: 315-322.
37. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, et al. (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 76: 2104-2111.
38. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, et al. (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127: 634-640.
39. Ahrens I, Lip GY, Peter K (2011) What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 105: 574-578.
40. Harenberg J, Marx S, Wehling M (2012) Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost 108: 407-409.
41. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, et al. (2012) Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 21: 429-435.
42. Lip GY, Frison L, Halperin JL, Lane DA (2010) Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41: 2731-2738.
43. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET (2013) New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis. Gastroenterology.
44. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.